Geode Capital Management
PHAT icon

Geode Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Geode Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3M Sell
1,315,687
-12,358
-0.9% -$141K ﹤0.01% 2349
2026
Q1 		$14.8M Buy
1,328,045
+254,611
+24% +$3.22M ﹤0.01% 2165
2025
Q4 		$17.8M Sell
1,073,434
-15,476
-1% -$221K ﹤0.01% 2072
2025
Q3 		$12.8M Buy
1,088,910
+18,983
+2% +$196K ﹤0.01% 2266
2025
Q2 		$10.3M Buy
1,069,927
+53,504
+5% +$296K ﹤0.01% 2348
2025
Q1 		$6.37M Sell
1,016,423
-2,072
-0.2% -$12.6K ﹤0.01% 2538
2024
Q4 		$8.27M Buy
1,018,495
+155,577
+18% +$1.93M ﹤0.01% 2480
2024
Q3 		$15.6M Buy
862,918
+56,871
+7% +$795K ﹤0.01% 2120
2024
Q2 		$8.3M Buy
806,047
+54,668
+7% +$563K ﹤0.01% 2441
2024
Q1 		$7.98M Buy
751,379
+16,106
+2% +$137K ﹤0.01% 2456
2023
Q4 		$6.71M Buy
735,273
+52,703
+8% +$454K ﹤0.01% 2553
2023
Q3 		$7.08M Buy
682,570
+192,447
+39% +$2.64M ﹤0.01% 2460
2023
Q2 		$7.02M Buy
490,123
+41,512
+9% +$479K ﹤0.01% 2507
2023
Q1 		$3.2M Buy
448,611
+13,567
+3% +$119K ﹤0.01% 2827
2022
Q4 		$4.88M Buy
435,044
+32,752
+8% +$338K ﹤0.01% 2681
2022
Q3 		$4.46M Buy
402,292
+55,356
+16% +$527K ﹤0.01% 2741
2022
Q2 		$2.93M Buy
346,936
+33,119
+11% +$341K ﹤0.01% 2978
2022
Q1 		$4.27M Buy
313,817
+20,619
+7% +$333K ﹤0.01% 2886
2021
Q4 		$5.77M Buy
293,198
+9,335
+3% +$220K ﹤0.01% 2819
2021
Q3 		$9.11M Buy
283,863
+2,490
+0.9% +$82.7K ﹤0.01% 2515
2021
Q2 		$9.52M Buy
281,373
+71,865
+34% +$2.57M ﹤0.01% 2491
2021
Q1 		$7.87M Buy
209,508
+32,034
+18% +$1.34M ﹤0.01% 2519
2020
Q4 		$5.89M Sell
177,474
-4,125
-2% -$167K ﹤0.01% 2515
2020
Q3 		$6.66M Buy
181,599
+3,257
+2% +$113K ﹤0.01% 2226
2020
Q2 		$5.87M Buy
178,342
+17,415
+11% +$669K ﹤0.01% 2240
2020
Q1 		$4.16M Buy
160,927
+7,493
+5% +$250K ﹤0.01% 2246
2019
Q4 		$4.78M Buy
+153,434
New +$3.86M ﹤0.01% 2485

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Geode Capital Management's PHAT Position: Q2 2026 in Review

Geode Capital Management reduced its Phathom Pharmaceuticals (PHAT) stake by 0.93% in Q2 2026, selling an estimated $141K and leaving 1,315,687 shares worth $14.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2349.

Geode Capital Management first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $17.8M in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Geode Capital Management held 1,315,687 shares of Phathom Pharmaceuticals worth $14.3M as of Q2 2026.
  • Geode Capital Management sold 12,358 Phathom Pharmaceuticals shares in Q2 2026, an estimated $141K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2349 holding.
  • Geode Capital Management first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Geode Capital Management's Phathom Pharmaceuticals position peaked at $17.8M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.